Amorphous formulation development - advantages and drawbacks

Research output: Contribution to journal › Conference article › Communication

Standard

Amorphous formulation development - advantages and drawbacks. / Kogermann, Karin ; Veski, Peep; Rantanen, Jukka; Naelapaa, Kaisa.

In: European Journal of Pharmaceutical Sciences, Vol. 44, No. supplement 1, 24.09.2011, p. 22-23.

Research output: Contribution to journal › Conference article › Communication

Harvard

Kogermann, K, Veski, P, Rantanen, J & Naelapaa, K 2011, 'Amorphous formulation development - advantages and drawbacks', European Journal of Pharmaceutical Sciences, vol. 44, no. supplement 1, pp. 22-23. https://doi.org/10.1016/j.ejps.2011.08.002

APA

Kogermann, K., Veski, P., Rantanen, J., & Naelapaa, K. (2011). Amorphous formulation development - advantages and drawbacks. European Journal of Pharmaceutical Sciences, 44(supplement 1), 22-23. https://doi.org/10.1016/j.ejps.2011.08.002

Vancouver

Kogermann K, Veski P, Rantanen J, Naelapaa K. Amorphous formulation development - advantages and drawbacks. European Journal of Pharmaceutical Sciences. 2011 Sep 24;44(supplement 1):22-23. https://doi.org/10.1016/j.ejps.2011.08.002

Author

Kogermann, Karin ; Veski, Peep ; Rantanen, Jukka ; Naelapaa, Kaisa. / Amorphous formulation development - advantages and drawbacks. In: European Journal of Pharmaceutical Sciences. 2011 ; Vol. 44, No. supplement 1. pp. 22-23.

Bibtex

@inproceedings{1ceb69d2f6c24b53859b8391e228bf05,
title = "Amorphous formulation development - advantages and drawbacks",
author = "Karin Kogermann and Peep Veski and Jukka Rantanen and Kaisa Naelapaa",
note = "doi:10.1016/j.ejps.2011.08.002",
year = "2011",
month = sep,
day = "24",
doi = "10.1016/j.ejps.2011.08.002",
language = "English",
volume = "44",
pages = "22--23",
journal = "Norvegica Pharmaceutica Acta",
issn = "0928-0987",
publisher = "Elsevier",
number = "supplement 1",

}

RIS

TY - GEN

T1 - Amorphous formulation development - advantages and drawbacks

AU - Kogermann, Karin

AU - Veski, Peep

AU - Rantanen, Jukka

AU - Naelapaa, Kaisa

N1 - doi:10.1016/j.ejps.2011.08.002

PY - 2011/9/24

Y1 - 2011/9/24

U2 - 10.1016/j.ejps.2011.08.002

DO - 10.1016/j.ejps.2011.08.002

M3 - Conference article

VL - 44

SP - 22

EP - 23

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

SN - 0928-0987

IS - supplement 1

ER -

ID: 34518028